financetom
Business
financetom
/
Business
/
Compass Reports Non-Reliance on 2022, 2023 Financial Results
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Compass Reports Non-Reliance on 2022, 2023 Financial Results
Jun 25, 2025 2:52 PM

05:41 PM EDT, 06/25/2025 (MT Newswires) -- Compass Diversified Holdings ( CODI ) reported late Wednesday

non-reliance on its financial statements for fiscal years 2022 and 2023 amid an ongoing probe into its subsidiary Lugano Holding.

In May, the company disclosed non-reliance on its 2024 financial statements. it had said the investigation found irregularities in Lugano's financing, accounting, and inventory practices.

Compass said it is focused on completing the probe, which is progressing in line with expectations, and working to finalize the necessary financial restatements.

The company added that the investigation is focused on Lugano and does not involve any of its other subsidiaries.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--Louisiana-Pacific Keeps Quarterly Dividend at $0.28 a Share, Payable Nov. 21 to Holders of Record Nov. 14
--Louisiana-Pacific Keeps Quarterly Dividend at $0.28 a Share, Payable Nov. 21 to Holders of Record Nov. 14
Oct 30, 2025
02:10 PM EDT, 10/30/2025 (MT Newswires) -- Price: 89.32, Change: +0.23, Percent Change: +0.26 ...
AstraZeneca Gefurulimab Shows Positive Phase 3 Results in Myasthenia Gravis Trial
AstraZeneca Gefurulimab Shows Positive Phase 3 Results in Myasthenia Gravis Trial
Oct 30, 2025
02:01 PM EDT, 10/30/2025 (MT Newswires) -- AstraZeneca ( AZN ) reported positive results from its Phase 3 trial of gefurulimab, showing statistically significant and clinically meaningful improvements in patients' ability to perform daily activities with generalized Myasthenia Gravis, a chronic autoimmune neuromuscular disorder. The trial met its primary endpoint, demonstrating a significant improvement in the Myasthenia Gravis Activities of...
Roblox Lifts 2025 Bookings Outlook, Flags Margin Pressures Amid Higher Spending
Roblox Lifts 2025 Bookings Outlook, Flags Margin Pressures Amid Higher Spending
Oct 30, 2025
02:05 PM EDT, 10/30/2025 (MT Newswires) -- Roblox ( RBLX ) raised its full-year bookings guidance, while the video game platform flagged potential margin pressures from increased investments in infrastructure and people. For fiscal 2025, the company now expects bookings of $6.57 billion to $6.62 billion, representing growth of 50% to 51% year over year, up from its prior outlook...
Abeona Therapeutics Gets Permanent CMS J-Code for Zevaskyn Gene Therapy
Abeona Therapeutics Gets Permanent CMS J-Code for Zevaskyn Gene Therapy
Oct 30, 2025
02:10 PM EDT, 10/30/2025 (MT Newswires) -- Abeona Therapeutics ( ABEO ) said Thursday its autologous gene therapy Zevaskyn received a permanent Healthcare Common Procedure Coding System J-code from the Centers for Medicare and Medicaid Services. The new product-specific identifier, J3389 - Topical administration, prademagene zamikeracel, per treatment - will take effect on Jan. 1, 2026, the company added. Zevaskyn...
Copyright 2023-2026 - www.financetom.com All Rights Reserved